3.27
-0.08 (-2.39%)
| Penutupan Terdahulu | 3.35 |
| Buka | 3.32 |
| Jumlah Dagangan | 2,369,182 |
| Purata Dagangan (3B) | 4,130,832 |
| Modal Pasaran | 991,334,784 |
| Harga / Jualan (P/S) | 13.54 |
| Harga / Buku (P/B) | 1.07 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| Margin Operasi (TTM) | -1,479.57% |
| EPS Cair (TTM) | -0.560 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -57.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 6.63% |
| Nisbah Semasa (MRQ) | 10.15 |
| Aliran Tunai Operasi (OCF TTM) | -78.40 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -189.06 M |
| Pulangan Atas Aset (ROA TTM) | -12.94% |
| Pulangan Atas Ekuiti (ROE TTM) | -15.60% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | AbCellera Biologics Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -3.5 |
| Osilator Teknikal | -0.5 |
| Purata | -1.00 |
|
AbCellera Biologics Inc is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company’s experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 22.97% |
| % Dimiliki oleh Institusi | 44.79% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 22 Jan 2026 | Pengumuman | AbCellera to Report Full Year 2025 Financial Results on February 24, 2026 |
| 12 Jan 2026 | Pengumuman | AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |